琥珀酸美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床效果分析

Analysis of clinical effect by metroprolol succinate combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure

目的探讨选择琥珀酸美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的临床效果。方法 102例冠心病心力衰竭患者,随机分为对照组和观察组,各51例。对照组患者给予常规治疗;在对照组治疗基础上,观察组患者给予琥珀酸美托洛尔联合曲美他嗪治疗。比较两组患者治疗效果以及左心室射血分数(LVEF)。结果观察组治疗总有效率为98.04%,高于对照组的74.51%,差异具有统计学意义(P<0.05)。治疗后为。治疗后,观察组LVEF水平为(50.15±11.38)%,高于对照组的(45.35±12.62)%,差异具有统计学意义(P<0.05)。结论对于冠心病心力衰竭患者的疾病症状表现加以明确后,除实施常规治疗之外,配合琥珀酸美托洛尔联合曲美他嗪治疗,患者心功能改善极为明显,最终获得确切的治疗效果。

Objective To investigate clinical effect by metroprolol succinate combined with trimetazidinein the treatment of patients with coronary heart disease and heart failure.Methods A total of102patients withcoronary heart disease and heart failure were randomly divided into control group and observation group,with51cases in each group.The control group received conventional therapy,and the observation group receivedadditional metroprolol succinate combined with trimetazidine to therapy in the control group.Comparison wasmade on curative effect and left ventricular ejection fraction(LVEF)between the two groups.Results Theobservation group had higher total effective rate in treatment as98.04%than74.51%in the control group,andthe difference had statistical significance(P<0.05).After treatment,the observation group had higher LVEF as(50.15±11.38)%than(45.35±12.62)%in the control group,and their difference had statistical significance(P<0.05).Conclusion After definition of symptom and manifestation in patients with coronary heart disease andheart failure,implement of additional metroprolol succinate combined with trimetazidine to conventional therapyshows remarkable improvement in cardiac function,along with precisely curative effect for patients.